Karl Swedberg

Summary

Country: Sweden

Publications

  1. doi request reprint Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    J Am Coll Cardiol 59:1938-45. 2012
  2. doi request reprint Treatment of anemia with darbepoetin alfa in systolic heart failure
    Karl Swedberg
    Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    N Engl J Med 368:1210-9. 2013
  3. doi request reprint Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    J Am Coll Cardiol 59:1598-603. 2012
  4. ncbi request reprint Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Lancet 376:875-85. 2010
  5. doi request reprint Successful treatment of heart failure with devices requires collaboration
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Eur J Heart Fail 10:1229-35. 2008
  6. doi request reprint Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, SE 416 85 Goteborg, Sweden
    Eur J Heart Fail 12:75-81. 2010
  7. ncbi request reprint [Preliminary version of the National Board of Health and Welfare's new guidelines for cardiac health care. Reliable knowledge material gives basis for better care]
    Karl Swedberg
    Kardiovaskulär medicin, Sahlgrenska akademin, Göteborgs Universitet
    Lakartidningen 104:3442-3. 2007
  8. ncbi request reprint Diagnostic and therapeutic algorithms in chronic heart failure
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Goteborg University, Gothenburg, Sweden
    Herz 31:877-90. 2006
  9. ncbi request reprint Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial
    Inger Ekman
    The Sahlgrenska Academy, Faculty of Health and Caring Sciences, Institute of Nursing, Goteborg University, Box 457, SE 405 30, Goteborg, Sweden
    Patient Educ Couns 61:348-53. 2006
  10. doi request reprint Risk following hospitalization in stable chronic systolic heart failure
    Putte Abrahamsson
    Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Eur J Heart Fail 15:885-91. 2013

Detail Information

Publications93

  1. doi request reprint Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    J Am Coll Cardiol 59:1938-45. 2012
    ..This study used the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) database to assess the impact of background beta-blocker dose on response to ivabradine...
  2. doi request reprint Treatment of anemia with darbepoetin alfa in systolic heart failure
    Karl Swedberg
    Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    N Engl J Med 368:1210-9. 2013
    ..We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic heart failure and anemia...
  3. doi request reprint Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    J Am Coll Cardiol 59:1598-603. 2012
    ..The purpose of this study was to analyze the incidence of new atrial fibrillation or flutter (AFF) in the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) database...
  4. ncbi request reprint Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Lancet 376:875-85. 2010
    ..Raised resting heart rate is a risk factor for adverse outcomes. We aimed to assess the effect of heart-rate reduction by the selective sinus-node inhibitor ivabradine on outcomes in heart failure...
  5. doi request reprint Successful treatment of heart failure with devices requires collaboration
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Eur J Heart Fail 10:1229-35. 2008
    ..Such team collaborations should lead to improved care with reduced mortality and morbidity and increased cost effectiveness. Treatment strategy should be based on a structured approach tailored to local practice and national priorities...
  6. doi request reprint Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT)
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, SE 416 85 Goteborg, Sweden
    Eur J Heart Fail 12:75-81. 2010
    ..The study will include approximately 6500 patients and will continue until > or =1600 primary endpoints have occurred. The first patient was randomized in October 2006, and the study is expected to end in 2010...
  7. ncbi request reprint [Preliminary version of the National Board of Health and Welfare's new guidelines for cardiac health care. Reliable knowledge material gives basis for better care]
    Karl Swedberg
    Kardiovaskulär medicin, Sahlgrenska akademin, Göteborgs Universitet
    Lakartidningen 104:3442-3. 2007
  8. ncbi request reprint Diagnostic and therapeutic algorithms in chronic heart failure
    Karl Swedberg
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Goteborg University, Gothenburg, Sweden
    Herz 31:877-90. 2006
    ..However, in some important aspects there can be differences in the interpretation of the evidence. A comparison of four major guideline documents was published recently...
  9. ncbi request reprint Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial
    Inger Ekman
    The Sahlgrenska Academy, Faculty of Health and Caring Sciences, Institute of Nursing, Goteborg University, Box 457, SE 405 30, Goteborg, Sweden
    Patient Educ Couns 61:348-53. 2006
    ..The objective was to describe perceptions about and adherence to regular medicines and study medication at baseline and study end in CHF patients participating in a clinical trial...
  10. doi request reprint Risk following hospitalization in stable chronic systolic heart failure
    Putte Abrahamsson
    Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Eur J Heart Fail 15:885-91. 2013
    ..We explored the impact of being hospitalized due to worsening heart failure (WHF) or a myocardial infarction (MI) on subsequent mortality in a large contemporary data set of patients with stable chronic systolic heart failure (HF)...
  11. doi request reprint Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993-2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden
    Masoud Shafazand
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Eur J Heart Fail 13:135-41. 2011
    ..To investigate temporal trends in the risk of heart failure (HF) complicating acute myocardial infarction (AMI) and to determine whether these trends differ by gender or age...
  12. doi request reprint Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure
    Putte Abrahamsson
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Eur Heart J 30:338-45. 2009
    ..We explored the impact of having a hospital admission for an acute coronary syndrome (ACS) on the subsequent prognosis among patients with chronic heart failure (CHF)...
  13. ncbi request reprint Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial
    Lars G Olsson
    Department of Emergency and Cardiovascular Medicine Sahlgrenska Academy, Goteborg University, Goteborg, Sweden, and Department of Cardiology, La Pitie Salpetriere Hospital, Paris, France
    Eur J Heart Fail 9:795-801. 2007
    ..Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis...
  14. ncbi request reprint [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)]
    Karl Swedberg
    Sahlgrenska Academy, The Göteborg University, Goteborg, Sweden
    Rev Esp Cardiol 58:1062-92. 2005
  15. ncbi request reprint Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program
    Lars G Olsson
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Am Coll Cardiol 47:1997-2004. 2006
    ....
  16. pmc Patients with worsening chronic heart failure who present to a hospital emergency department require hospital care
    Masoud Shafazand
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Sahlgrenska University Hospital Ostra, University of Gothenburg, Gothenburg, Sweden
    BMC Res Notes 5:132. 2012
    ..To characterise patients with CHF who seek an emergency department (ED) because of worsening symptoms and signs and to explore the reasons why they are admitted to hospital...
  17. ncbi request reprint Uncertainty in illness among patients with chronic heart failure is less in person-centred care than in usual care
    Kerstin Dudas
    1Institute of Health and Care Science, Gothenburg, Sweden
    Eur J Cardiovasc Nurs 12:521-8. 2013
    ..The impact of PCC on self-reported uncertainty in illness among patients hospitalized for CHF is still unknown...
  18. ncbi request reprint Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 26:1303-8. 2005
    ..Atrial fibrillation is common in patients with chronic heart failure (CHF). We analysed the risk associated with atrial fibrillation in a large cohort of patients with chronic heart failure all treated with a beta-blocker...
  19. ncbi request reprint [Diagnosis and treatment of chronic heart disease. Guidelines of the European Society of Cardiology. Revision 2005]
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Kardiol Pol 63:509-43; discussion 544-8. 2005
  20. doi request reprint Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study
    Inger Ekman
    Institute of Health and Care Sciences, Sahlgrenska Academy, Box 457, SE 405 30 Gothenburg, Sweden
    Eur Heart J 32:2395-404. 2011
    ..The aim was to evaluate whether heart rate (HR) reduction with ivabradine can translate into increased HQoL in parallel to a reduction of primary outcomes in SHIFT...
  21. ncbi request reprint Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction
    Natalie A Bello
    From the Department of Medicine, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA N A B, B C, A S D, M A P, S D S Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom J J V M Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC C B G Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada S Y and Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden K S
    Circ Heart Fail 7:590-5. 2014
    ....
  22. pmc Effects of person-centred care in patients with chronic heart failure: the PCC-HF study
    Inger Ekman
    Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, Gothenburg 40530, Sweden
    Eur Heart J 33:1112-9. 2012
    ....
  23. doi request reprint Home care as an option in worsening chronic heart failure -- a pilot study to evaluate feasibility, quality adjusted life years and cost-effectiveness
    Harshida Patel
    Institute of Health and Care Sciences, Sahlgrenska Academy, Sweden
    Eur J Heart Fail 10:675-81. 2008
    ..Worsening chronic heart failure (CHF) is largely characterized by frequent hospital admissions and the need for specialist care...
  24. doi request reprint Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry
    Masoud Shafazand
    Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, Sahlgrenska University Hospital Ostra, University of Gothenburg, S 416 85 Goteborg, Sweden
    Eur Heart J 30:671-8. 2009
    ..To investigate gender-specific trends in long-term mortality in patients hospitalized for heart failure (HF)...
  25. ncbi request reprint Salt and fluid restriction is effective in patients with chronic heart failure
    Henriette Philipson
    University of Goteborg, Sahlgrenska Academy, Goteborg, Sweden
    Eur J Heart Fail 15:1304-10. 2013
    ..Therefore, we investigated the effects of salt and fluid restriction in patients with CHF...
  26. ncbi request reprint Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review
    Lars G Olsson
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 26:778-93. 2005
    ..The aim of this study is to investigate, using a systematic literature review, the utility of the 6MWT as a measure of the effectiveness of treatment in randomized controlled trials of heart failure...
  27. ncbi request reprint Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000
    Maria Schaufelberger
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Eur Heart J 25:300-7. 2004
    ..To investigate if improved treatment of coronary heart disease and hypertension, the major causes of chronic heart failure (CHF), in the last 20 years has had an impact on the incidence of CHF and survival...
  28. pmc Impacts of patient characteristics on hospital care experience in 34,000 Swedish patients
    Axel Wolf
    Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    BMC Nurs 11:8. 2012
    ..abstract:..
  29. doi request reprint A pilot study of salt and water restriction in patients with chronic heart failure
    Henriette Philipson
    Department of Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden
    Scand Cardiovasc J 44:209-14. 2010
    ..Urine sodium excretion was measured on three consecutive days and para-aminobenzoic acid was used to secure urine collection. Individual dietary recommendations were provided...
  30. doi request reprint Impact of device-guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study
    Inger Ekman
    Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden
    Eur J Heart Fail 13:1000-5. 2011
    ..The aim of this study was to investigate if lowering breathing rate with the help of a respiratory modulation (RM) device could improve symptoms in patients with CHF...
  31. doi request reprint Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men
    Annika Rosengren
    Department of Medicine, Sahlgrenska University Hospital Ostra, Göteborg SE 416 85, Sweden
    Eur Heart J 30:1113-20. 2009
    ..Obesity is a recognized risk factor for atrial fibrillation (AF), partly because of the association between body mass index (BMI) and atrial volume. We aimed to determine whether other factors relating to body size were related to AF...
  32. pmc Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden
    Anders Barasa
    Department of Molecular and Clinical Medicine, Institute of Medicine Cardiology, Sahlgrenska Academy, University of Gothenburg, Ostra, Gothenburg SE 416 85, Sweden
    Eur Heart J 35:25-32. 2014
    ..To describe trends in incidence and case fatality among younger (18-54 years) and older (55-84 years) Swedish patients with heart failure (HF)...
  33. ncbi request reprint QRS aberration during atrial fibrillation at rest and during exercise. Effect of a selective potassium channel blocking agent
    Birgitta Houltz
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    J Electrocardiol 35:201-12. 2002
    ..In conclusion, aberrant conduction is common during infusion of the I(kr)-blocker almokalant during AF, and seems to be more frequent in females and in patients with more advanced myocardial disease...
  34. ncbi request reprint Standard medication information is not enough: poor concordance of patient and nurse perceptions
    Inger Ekman
    Institute of Health and Care Sciences, The Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    J Adv Nurs 60:181-6. 2007
    ..This paper is a report of a study to describe patient and nurse perceptions of patient satisfaction with information about the medicines at two heart failure clinics after medication up-titration and information-giving...
  35. doi request reprint Trends in stroke incidence after hospitalization for atrial fibrillation in Sweden 1987 to 2006
    Lars G Olsson
    Department of Medicine, Mora Hospital, Mora, Sweden
    Int J Cardiol 167:733-8. 2013
    ..To investigate recent trends in incidence of hemorrhagic and non-hemorrhagic strokes in patients with atrial fibrillation (AF)...
  36. doi request reprint Efficacy of person-centred care as an intervention in controlled trials - a systematic review
    Lars Eric Olsson
    Institute of Health and Care Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    J Clin Nurs 22:456-65. 2013
    ..To identify person-centred care as an intervention in controlled trials, where patients had been involved as a partner, and to describe the outcomes of these studies...
  37. doi request reprint Person-centered care--ready for prime time
    Inger Ekman
    Institute of Health and Care Sciences, Department of Emergency and Cardiovascular Medicine, Sahlgrenska Academy, University of Gothenburg, Box 457, 405 30 Gothenburg, Sweden
    Eur J Cardiovasc Nurs 10:248-51. 2011
    ..We believe that if conscientiously and systematically applied, they will help to make PCC the focus and mainstay of care in long-term illness...
  38. doi request reprint Measuring shortness of breath in heart failure (SOB-HF): development and validation of a new dyspnoea assessment tool
    Inger Ekman
    Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Box 457, SE 405 30 Gothenburg, Sweden
    Eur J Heart Fail 13:838-45. 2011
    ..To validate a previously developed instrument for measurement of breathlessness in patients with acute heart failure (HF)...
  39. ncbi request reprint Fibrinolytic capacity increases with age in healthy humans, while endothelium-dependent vasodilation is unaffected
    Thorarinn Gudnason
    Department of Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Thromb Haemost 89:374-81. 2003
    ..008) in the age-quartiles, respectively. A similar significant age-related response was observed for tPA activity. We conclude that in healthy individuals there is an up-regulation of the fibrinolytic response by age...
  40. ncbi request reprint Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Circulation 105:1797-803. 2002
    ..We investigated the dose-response relationship of a new sustained-release (SR) preparation of moxonidine and the plasma concentration of norepinephrine in patients with chronic heart failure...
  41. ncbi request reprint Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial
    Robert J Mentz
    From the Duke University Medical Center, Durham, NC R J M Northwestern University Feinberg School of Medicine, Chicago, IL S J G Stanford University School of Medicine, CA A P A Massachusetts General Hospital, Boston M V Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL H P S, M G Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden K S Associazione Nazionale Medici Cardiologi Ospedalieri Research Center, Florence, Italy A P M University of Brescia, Brescia, Italy Klinika Kardiologii, Wroclaw, Poland S N, P P Center for Clinical and Basic Research, IRCCS San Raffaele, Rome, Italy S D A and Emory University, Atlanta, GA J B
    Circ Heart Fail 7:401-8. 2014
    ..Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge...
  42. ncbi request reprint [Diagnosis and treatment of acute heart failure. Guidelines of the European Society of Cardiology]
    Markku S Nieminen
    Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland
    Kardiol Pol 63:143-86; discussion 187-9. 2005
  43. pmc Heart failure guidelines and prescribing in primary care across Europe
    Heidrun B Sturm
    Department of Clinical Pharmacology, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    BMC Health Serv Res 5:57. 2005
    ..National guideline recommendations might be a relevant factor. This study, therefore, explored variation of heart failure guideline recommendations in Europe...
  44. ncbi request reprint Patients' persistence of evidence-based treatment of chronic heart failure: a treatment paradox
    Inger Ekman
    Circulation 116:693-5. 2007
  45. ncbi request reprint Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
    ..We investigated the effect of addition of an angiotensin-receptor blocker to current treatments...
  46. ncbi request reprint Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure Survey analysis
    Mitja Lainscak
    Department of Internal Medicine, General Hospital Murska Sobota, Murska Sobota, Slovenia
    Eur J Heart Fail 9:1095-103. 2007
    ..There are limited data on recall and implementation of lifestyle advice in patients with heart failure (HF)...
  47. ncbi request reprint Breaking the vicious circle of fatigue in patients with chronic heart failure
    Kristin Falk
    Institute of Health and Care Sciences, Goteborg University
    Qual Health Res 17:1020-7. 2007
    ..The restoring activities included the categories involuntarily attentive, socially interactive, and mentally absorbed. Interventions aimed to relieve fatigue should focus on restorative activities...
  48. ncbi request reprint The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and M
    Hertzel C Gerstein
    Department of Medicine and the Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada
    Arch Intern Med 168:1699-704. 2008
    ..To our knowledge, the nature of such a relationship in patients with symptomatic chronic heart failure (HF) has not been studied...
  49. ncbi request reprint Spotlight: Karl Swedberg, MD, PhD, FESC. Interview by Barry Shurlock
    Karl Swedberg
    Circulation 117:f17-8. 2008
  50. ncbi request reprint The CHARM program: study design leads to findings of clinical and public health importance
    Charles H Hennekens
    Florida Atlantic University, Boca Raton, Florida, and Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Cardiovasc Pharmacol Ther 12:124-6. 2007
    ..Such patients have a 50% mortality rate at 5 years, and heart failure is the leading cause of hospitalization for patients 65 years of age and older...
  51. ncbi request reprint Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials
    Leonardo De Luca
    Division of Cardiology, European Hospital, Rome, Italy
    Acute Card Care 9:10-21. 2007
    ..Acute Heart Failure Syndromes (AHFS) is a common admission diagnosis associated with high mortality and hospital readmissions. Given the mixed results of recent clinical trials, the early management of AHFS remains controversial...
  52. ncbi request reprint [Expert Consensus document on beta-adrenergic receptor blockers]
    Jose Lopez-Sendon
    Rev Esp Cardiol 58:65-90. 2005
  53. ncbi request reprint [Expert Consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease]
    Jose Lopez-Sendon
    Rev Esp Cardiol 57:1213-32. 2004
  54. ncbi request reprint Conclusions on the management of heart failure
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital, Gothernburg, Sweden
    J Renin Angiotensin Aldosterone Syst 5:S34-6. 2004
    ..It is desirable to use multiple agents for best results in patients with heart failure. New European Society of Cardiology guidelines on the management of heart failure are expected later this year...
  55. ncbi request reprint Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials
    James B Young
    Division of Medicine, The Cleveland Clinic Foundation and Kaufman Center for Heart Failure, 9500 Euclid Avenue T 13, Cleveland, OH 44195, USA
    Circulation 110:2618-26. 2004
    ..CHARM is a randomized, double-blind, placebo-controlled, multicenter, international trial program...
  56. ncbi request reprint Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02445, USA
    Circulation 110:2180-3. 2004
    ..We assessed the effect of candesartan on cause-specific mortality in patients enrolled in the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program...
  57. ncbi request reprint Can brain natriuretic peptide (BNP) be used as a screening tool in general practice?
    Maria Schaufelberger
    Department of Cardiology, Mölnlycke Primary Health Care and Research Centre, Molnlycke, Sweden
    Scand J Prim Health Care 22:187-90. 2004
    ..To investigate plasma brain natriuretic peptide (p-BNP) in consecutive primary care patients for heart failure screening...
  58. ncbi request reprint Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology
    Jose Lopez-Sendon
    Cardiology, Hospital Universitario Gregorio Maranon, Madrid, Spain
    Eur Heart J 25:1454-70. 2004
  59. ncbi request reprint Expert consensus document on beta-adrenergic receptor blockers
    Jose Lopez-Sendon
    Cardiology, Hospital Universitario Gregorio Maranon, Madrid, Spain
    Eur Heart J 25:1341-62. 2004
  60. ncbi request reprint A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
    John G F Cleland
    University of Hull, Kingston upon Hull, UK
    Cardiovasc Drugs Ther 18:139-52. 2004
    ..The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics...
  61. ncbi request reprint Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  62. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    Christopher B Granger
    Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 362:772-6. 2003
    ..We aimed to find out whether candesartan, an angiotensin-receptor blocker, could improve outcome in such patients not taking an ACE inhibitor...
  63. ncbi request reprint Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    John J V McMurray
    University of Glasgow, Glasgow, UK
    Lancet 362:767-71. 2003
    ..We aimed to find out whether these drugs improve clinical outcome...
  64. ncbi request reprint Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Lancet 362:759-66. 2003
    ..Patients with chronic heart failure (CHF) are at high risk of cardiovascular death and recurrent hospital admissions. We aimed to find out whether the use of an angiotensin-receptor blocker could reduce mortality and morbidity...
  65. ncbi request reprint [A study of primary health care in 15 different countries. Examination and treatment of patients with heart failure should be better]
    Charles Cline
    Kardiologkliniken, Universitetssjukhuset MAS, Malmo
    Lakartidningen 100:1242-3. 2003
  66. ncbi request reprint Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan
    Mark S Hansen
    Division of Cardiology of the University Health Network and Mount Sinai Hospital, Toronto, Ontario, Canada
    Am J Cardiol 90:969-73. 2002
    ..Flosequinan treatment eliminates this association, highlighting the complexity of the relation between cardiac myocyte damage, drug treatment, and mortality...
  67. ncbi request reprint Pathophysiologic and therapeutic importance of tissue ACE: a consensus report
    Victor J Dzau
    Department of Medicine, Brigham Women s Hospital, Boston, MA 02115, USA
    Cardiovasc Drugs Ther 16:149-60. 2002
    ..Pharmacologic studies show that while ACE inhibitors may differ according to their binding affinity for tissue ACE the clinical significance remains to be determined...
  68. ncbi request reprint Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, Dovehouse Street, London, SW3 6LY, UK
    Eur J Heart Fail 4:321-9. 2002
    ..The target dose for carvedilol is 25 mg bid and for metoprolol tartrate 50 mg bid. This manuscript outlines the rationale, design and possible outcomes of COMET...
  69. ncbi request reprint [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]
    Markku S Nieminen
    Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland markku nieminen hus fi
    Rev Esp Cardiol 58:389-429. 2005
  70. ncbi request reprint Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
    Karl Swedberg
    Sahlgrenska Academy at the Göteborg University, Department of Medicine, Sahlgrenska University Hospital, Sweden
    Eur Heart J 26:1115-40. 2005
  71. ncbi request reprint [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]
    Markku S Nieminen
    Ital Heart J Suppl 6:218-54. 2005
  72. ncbi request reprint Heart failure management. Interview with Karl Swedberg
    Karl Swedberg
    Timely Top Med Cardiovasc Dis 11:E1. 2007
  73. pmc Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen NV, Denmark
    Heart 93:968-73. 2007
    ..Beta blocker treatment may worsen glucose metabolism...
  74. ncbi request reprint Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge
    Nasrin K Khan
    University of Hull, Kingston upon Hull, United Kingdom
    Eur J Heart Fail 9:491-501. 2007
    ..Most patients suspected of having heart failure (HF) will get a 12-lead electrocardiogram (ECG) but its utility for excluding HF or assisting in its management has rarely been investigated...
  75. ncbi request reprint Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I
    Michel Komajda
    Department of Cardiology, Pitie Salpetriere Hospital, University Pierre et Marie Curie, 47 83 boulevard de l Hopital, 75013 Paris, France
    Eur Heart J 28:1310-8. 2007
    ..Here, the aim is to study the management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Heart Failure (HF) is common in older people and associated with poor outcome...
  76. ncbi request reprint International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey
    Mitja Lainscak
    Department of Internal Medicine, General Hospital Murska Sobota, Murska Sobota, Slovenia
    Eur J Heart Fail 9:292-9. 2007
    ..This may reflect a lack of adequate organisation of care or co-morbidity contra-indicating therapy...
  77. ncbi request reprint Fatigue is a prevalent and severe symptom associated with uncertainty and sense of coherence in patients with chronic heart failure
    Kristin Falk
    Institute of Health and Care Sciences, The Sahlgrenska Academy at Goteborg University, Box 457, S 405 30 Goteborg, Sweden
    Eur J Cardiovasc Nurs 6:99-104. 2007
    ....
  78. ncbi request reprint Treatment of chronic heart failure: a comparison between the major guidelines
    John McMurray
    Department of Cardiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Eur Heart J 27:1773-7. 2006
    ..Possible explanations for discrepancies between the guidelines are discussed. Future approaches that might clarify the grade of evidence allocated and class of recommendation made are also described...
  79. ncbi request reprint Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    John J V McMurray
    Department of Cardiology, Level 4, Western Infirmary, Glasgow, Scotland, UK
    Eur Heart J 27:1447-58. 2006
    ..We have carried out a prospective economic analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme...
  80. ncbi request reprint A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
    John G F Cleland
    Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
    J Am Coll Cardiol 47:1603-11. 2006
    ..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
  81. ncbi request reprint Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction
    Lars Køber
    Department of Cardiology, Non Invasive Lab, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark
    Eur J Heart Fail 8:591-8. 2006
    ....
  82. ncbi request reprint The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, Scotland, United Kingdom
    J Am Coll Cardiol 47:726-33. 2006
    ..We attempted to compare the effect of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events...
  83. ncbi request reprint Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial
    Bradi B Granger
    Duke University Medical Center and Duke University School of Nursing, Durham, NC, USA
    Lancet 366:2005-11. 2005
    ....
  84. ncbi request reprint Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02445, USA
    Circulation 112:3738-44. 2005
    ..The growing number of patients with preserved systolic function heart failure underscores the importance of understanding the relationship between ejection fraction and risk...
  85. ncbi request reprint Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure
    Mattie J Lenzen
    Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands
    Eur Heart J 26:2706-13. 2005
    ..Evidence-based medicine and clinical guidelines are based on the results of randomized controlled trials. Therefore, we investigated how patients who fulfilled the enrolment criteria of randomized trials were treated in real life...
  86. ncbi request reprint Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice
    John McMurray
    Department of Cardiology, Western Infirmary, Glasgow, G12 8QQ, UK
    Eur J Heart Fail 7:710-21. 2005
    ..These practical recommendations are meant to serve as a supplement to, rather than replacement of, existing HF guidelines...
  87. ncbi request reprint The relevance of comorbidities for heart failure treatment in primary care: A European survey
    Heidrun B Sturm
    Department of Clinical Pharmacology, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
    Eur J Heart Fail 8:31-7. 2006
    ..To assess the impact of comorbidities on chronic heart failure (CHF) therapy...
  88. ncbi request reprint Gender makes a difference in the description of dyspnoea in patients with chronic heart failure
    Inger Ekman
    Faculty of Health and Caring Sciences, Institute of Nursing, The Sahlgrenska Academy at Goteborg University, Box 457, Göteborg SE 405 30, Sweden
    Eur J Cardiovasc Nurs 4:117-21. 2005
    ..Dyspnoea is a common symptom of chronic heart failure (CHF). In the community setting, patients with CHF are most often women...
  89. ncbi request reprint Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology
    Willem J Remme
    Sticares, Cardiovascular Research Foundation, P O Box 882, 3160 AB, Rhoon, The Netherlands
    Eur J Heart Fail 4:11-22. 2002